Z-VAD-FMK C22H30FN307 

To Order Contact us: stephen@expresspharmapulse.com

Z-VAD-FMK

A1902-25 25 mg
EUR 514
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2.

Z-VAD-FMK

A1902-5 5 mg
EUR 224
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2.

Z-VAD-FMK

A1902-5.1 10 mM (in 1mL DMSO)
EUR 224
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2.

Z-VAD-FMK

1140-1
EUR 294

Z-VAD-FMK

1140-5
EUR 805

Z-VAD(OMe)-FMK

HY-16658 10mg
EUR 394

Z-VAD-FMK, cell permeable

GL1523-1MG 1 mg
EUR 275

Z-VAD-FMK, cell permeable

GL1523-5MG 5 mg
EUR 792

Caspase-Family Inhibitor Z-VAD-FMK

1010-100
EUR 196

Caspase-Family Inhibitor Z-VAD-FMK

1010-20C
EUR 196

SRB-VAD-FMK [Sulforhodamine B-VAD-FMK]

13472 25 Tests
EUR 132
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 12352200

Z-VAD-FMK (Pan-specific caspase inhibitor)

SIH-557-1MG 1 mg
EUR 193
Description: The substance Z-VAD-FMK is a pan-specific caspase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is lyophilized solid or wax which is May be dissolved in DMSO (10 mg/ml).

Biotin-VAD-FMK

HY-100894 1mg
EUR 1014

FITC-VAD-FMK

9497-100
EUR 359

Biotin-VAD-FMK

1123-20C
EUR 327

TF4-VAD-FMK

13471 25 Tests
EUR 132
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 12352200

mFluor™ 450-VAD-FMK

13475 25 Tests
EUR 132
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 12352200

mFluor™ 510-VAD-FMK

13476 25 Tests
EUR 132
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 12352200

Z-IETD-FMK

B3232-1 1 mg
EUR 328
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells.

Z-IETD-FMK

B3232-5 5 mg
EUR 456
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells.

Z-IETD-FMK

B3232-5.1 10 mM (in 1mL DMSO)
EUR 1001
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells.

Z-LEHD-FMK

B3233-1 1 mg
EUR 350
Description: Z-LEHD-FMK is a specific and irreversible inhibitor of caspase-9 [1].Caspase-9 is an initiator caspase and plays an important role in the mitochondrial death pathway.

Z-LEHD-FMK

B3233-5 5 mg
EUR 879
Description: Z-LEHD-FMK is a specific and irreversible inhibitor of caspase-9 [1].Caspase-9 is an initiator caspase and plays an important role in the mitochondrial death pathway.

Z-AEVD-FMK

B1162-1
EUR 338

Z-VRPR-FMK

B1238-1000
EUR 914

Z-VRPR-FMK

B1238-250
EUR 338

Z-IETD-FMK

HY-101297 5mg
EUR 463

Z-DEVD-FMK

HY-12466 10mg
EUR 393

Z-VRPR-FMK

GL3755-1MG 1 mg
EUR 585

Z-VRPR-FMK

GL3755-500UG 500 ug
EUR 355

Z-DEVD-FMK

A1920-1 1 mg
EUR 113
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK

A1920-10 10 mg
EUR 340
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK

A1920-25 25 mg
EUR 514
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK

A1920-5 5 mg
EUR 224
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK

A1920-5.1 10 mM (in 1mL DMSO)
EUR 293
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK

A1920-S Evaluation Sample
EUR 81
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DQMD-FMK

A1921-1 1 mg
EUR 113
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK

A1921-10 10 mg
EUR 340
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK

A1921-25 25 mg
EUR 514
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK

A1921-5 5 mg
EUR 224
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK

A1921-5.1 10 mM (in 1mL DMSO)
EUR 432
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK

A1921-S Evaluation Sample
EUR 81
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-VDVAD-FMK

A1922-1 1 mg
EUR 177
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK

A1922-10 10 mg
EUR 630
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK

A1922-25 25 mg
EUR 978
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK

A1922-5 5 mg
EUR 398
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK

A1922-S Evaluation Sample
EUR 81
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VEID-FMK

A1923-1 1 mg
EUR 177
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK

A1923-10 10 mg
EUR 630
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK

A1923-25 25 mg
EUR 978
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK

A1923-5 5 mg
EUR 398
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK

A1923-S Evaluation Sample
EUR 81
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-WEHD-FMK

A1924-1 1 mg
EUR 113
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-WEHD-FMK

A1924-10 10 mg
EUR 340
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-WEHD-FMK

A1924-25 25 mg
EUR 514
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-WEHD-FMK

A1924-5 5 mg
EUR 224
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-VAD-FMK C22H30FN307